Please login to the form below
ulcerative colitis
This page shows the latest ulcerative colitis news and features for those working in and with pharma, biotech and healthcare.
Novartis’ Mayzent and Roche’s Polivy lead CHMP recommendations
patients with ulcerative colitis – unless there is no alternative treatment.
Latest news
-
Janssen files Tremfya for psoriatic arthritis in Europe
indications like PsA, Crohn’s disease, and ulcerative colitis – to compensate.
-
Transformation in healthcare professionals’ digital behaviours
One recent example of this came from Pfizer’s Twitter account as it shared a portrait-orientated video showing ulcerative colitis (UC) patients discussing how they felt opening up about their
-
NICE’s fast-track catapults Skyrizi into market
contested inflammation and immunology indications as well, such as Crohn’s and ulcerative colitis.
-
Takeda makes Crohn’s disease case for subcutaneous Entyvio
to compete strongly against well-established ulcerative colitis drugs such as Humira and Johnson &Johnson’s Simponi (golimumab). ... Takeda has already filed the new formulation for ulcerative colitis in the US and Europe.
-
AbbVie’s Skyrizi gets rapid ‘yes’ from NICE
contested inflammation and immunology indications as well, such as Crohn’s and ulcerative colitis.
More from news
Approximately 20 fully matching, plus 115 partially matching documents found.
Latest Intelligence
-
Taking a lean and careful approach
ulcerative colitis, type 1 diabetes and inflammatory bowel disease.
-
Making digital health personal
Personalisation: A case study. This case study is of a digital health support programme that improved persistence of people with ulcerative colitis.
-
Deal Watch January 2017
Assembly Biosciences. Allergan. Exclusive global licence . 2 pc candidates for ulcerative colitis (ABI-M201) and Crohn's disease plus 2 compounds for IBS.
-
Forging a path in specialty care
Adcetris (for Hodgkin Lymphoma), Entyvio (for ulcerative colitis and Crohn's Disease) and future compound Ninlaro (an oral protease inhibitor for relapsed/refractory multiple myeloma) which was approved by the FDA
-
Biosimilars - the same, but different?
The first months of 2015 also saw it approve Remsima and Inflectra for use on the NHS to treat moderately to severely active ulcerative colitis after the failure of conventional therapy.
More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.
Latest appointments
-
Lorin Johnson joins Atlantic Healthcare board
Atlantic's lead asset, alicaforsen for the treatment of the inflammatory bowel diseases ulcerative colitis and pouchitis.
-
Ex J&J VP joins board of Immune
Its lead product candidate is bertilimumab, which is in clinical development for ulcerative colitis and Crohn's Disease as well as the rare skin condition bullous pemphigoid.
-
AstraZeneca veteran Deborah Hartman joins Avaxia
Will lead the development of AVX-470 in ulcerative colitis. Former AstraZeneca (AZ) vice president Dr Deborah Hartman has joined Avaxia Biologics as VP research, replacing Dan Tracey who retires. ... with active ulcerative colitis.
-
EMA’s Pharmacovigilance Risk Assessment Committee gains new members
Their respective alternates are Kirsten Myhr, from the Norwegian Board of Health, and Marco Greco, from the European Federation Crohn's and Ulcerative Colitis Associations.
More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
Cello Health Insight wins EphMRA’s 2019 Market Research Excellence Award for 'Business Impact through Innovation'
The winning entry focused on exploring the Crohn’s Disease and Ulcerative Colitis patient journeys – mapping the transactional touchpoints and overlaying the emotional experience of patients so that Janssen could gauge
-
emotive adds to medical team with new Scientific Lead and Associate Medical Writer
Kate is experienced in a wide range of therapy areas, including immunology, specifically Crohn’s disease, ulcerative colitis and psoriatic arthritis, in ophthalmology, including retinal diseases, glaucoma and dry eye disease,
-
Research Partnership has published a new Living with Ulcerative Colitis (UC) US market report for 2017
Living with Ulcerative Colitis (UC) is a study conducted amongst 110 adult UC patients in the US. ... The study employs a mixed quantitative/qualitative methodology and is available to purchase alongside our Living with Ulcerative Colitis 2016 5EU report.
-
Research Partnership launches new patient Living with Ulcerative Colitis (UC) US report
Living with Ulcerative Colitis (UC) is a study conducted amongst 100 adult UC patients in the US.
-
Lucid win PMEA Support Agency of the Year 2016
Highly Commended: Excellence in Healthcare Collaboration and Partnerships – The Ulcerative Colitis Endoscopic Index of Severity Online Tool . Jan Steele (Lucid Co-Founder andCOO) commented: “Being recognised for our work at these
More from PMHub
Approximately 4 fully matching, plus 8 partially matching documents found.
Featured jobs
-
Account Director, Medical Education
-
Salary TBC
-
Account Director
-
Salary TBC
- Scientific Director - Medical Communications Agency - New York
-
Excellent Remuneration Package
- Scientific Director - Medical Education - Cheshire & London ...
-
Excellent Remuneration Package
-
Account Executive
-
Salary TBC
- Graduate / Entry Level Opportunities – Medical Communications – ...
-
Highly Competitive Remuneration Package
- Entry Level Editorial Assistant – Medical Education –Buckinghams...
-
Highly Competitive
- Senior Editor - Medical Communications - South East - Buckingham...
-
Highly competitive salary &package
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Experienced / Senior Medical Writer - MedComms - Cardiff - Wales
-
Excellent Salary and Benefits on offer
- Senior / Principal Medical Writer – Medical Education - UK &...
-
Excellent Salary and Benefits on offer
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
- Senior Medical Writer– Medical Education – Oxford - London
-
Excellent Remuneration Package
- Scientific Director - Medical Communications - Berkshire
-
Excellent package on offer
- Senior Medical Writer – Leading Medical Communications Agency – ...
-
Highly Competitive Remuneration Package
-
Account Supervisor
-
Salary TBC
-
Senior Medical Writer
-
Salary TBC
Subscribe to our email news alerts
- Takeda highlights 12 NMEs with $10bn-plus sales potential at R&D day
- MSD hangs ‘for sale’ sign on French facility, shedding 207 staff
- Nucala works in rare inflammatory disease, says GSK
- MSD hangs ‘for sale’ sign on French facility, shedding 207 staff
- Otsuka presses on with Alzheimer’s agitation drug
- Four Ms
- Using human insights to push healthcare communications forward
- RWE Blog 4: The place of real-world evidence in the market access strategy
- Don’t we all need to be able to change something?
- Antibiotic resistance: The silent pandemic
- BMS, Celgene merger should close this week after FTC okay
- The NHS is facing shortages of lifesaving treatments, says internal document
PMHub
Branding Science
We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...
Latest intelligence
- Using human insights to push healthcare communications forward
- This blog highlights the value of human perspectives, showing how insights can propel healthcare communications forward to ultimately improve lives...
- RWE Blog 4: The place of real-world evidence in the market access strategy
- The fourth and final blog in our latest series focuses on market access strategy. This follows our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in...
- RWE Blog 3: Is real-world evidence the holy grail
- We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...
Quick links
Infographics
